Takeda Pharmaceutical Co., Japan's largest drugmaker, expects a 55 percent decline in profit this year from costs related to the $8.8 billion takeover of Millennium Pharmaceutical Inc. last month.
Net income will fall to ¥160 billion for the year ending next March 31, the firm said Friday in a statement to the Tokyo Stock Exchange.
Buying Cambridge, Mass.-based Millennium gives Takeda drugs under trial to treat cancer and inflammation, as well as additional research costs. Osaka-based Takeda needs the products because patents on its Actos diabetes treatment and stomach ulcer medicine Prevaid will expire within three years.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.